Becton Dickinson and Co. will report fiscal third-quarter earnings Thursday before the market opens, giving investors their first look at how the medical-technology company is navigating life after its landmark divestiture of its biosciences business.
Analysts expect the company to post earnings of $2.78 a share on revenue of $4.67 billion, marking a sequential decline from the $2.91 per share and $5.30 billion the company reported in its February quarter. The revenue drop largely reflects the completion of BD’s Reverse Morris Trust transaction with Waters Corporation, which separated its Biosciences and Diagnostic Solutions segments in February 2026.
Analysts rate the stock a Buy with a mean price target of $188.79, implying 30.95% upside from the current $144.17 price. Revenue estimates have risen modestly over the past week and two months, while EPS estimates have edged down slightly over the past 60 days.
What Investors Are Watching
The key question is whether BD’s "pure-play" medical technology strategy can deliver the mid-single digit organic growth that management has articulated. Evercore ISI analyst Vijay Kumar noted that while reported organic growth has trended in the low-single digits, "excluding one timers, BD is growing ~MSD on an underlying basis."
Investors will scrutinize whether transitory headwinds are stabilizing or intensifying. China’s volume-based procurement policies have squeezed margins on high-volume medical supplies, and BD has responded by localizing manufacturing, but geopolitical risk remains high. Management previously indicated these combined headwinds from China, vaccines and the Alaris infusion pump business would represent about 250 basis points of impact for the year.
The company has laid out six growth drivers—including opportunities around GLP-1s/biologics, pharmacy automation, peripheral access, hernia, urinary incontinence and advanced patient monitoring—that "cumulatively account for ~25% of revs which could growth at 9-10% going forward." Evidence of traction in these areas would support the bull case that BD’s growth profile is improving beneath the surface.
Margin expansion will also be in focus. Argus analyst David Toung noted the company’s "strategy of focusing on faster-growing opportunities in the Medical and Interventional segments after divesting its Biosciences and Diagnostics business," which provided $4 billion in cash for share repurchases, debt reduction and internal investments.
Prior Quarter Strength
BD last reported first fiscal quarter 2026 results in February that beat expectations, posting EPS of $2.91 versus the $2.81 forecast and revenue of $5.30 billion versus the $5.15 billion estimate. Management highlighted double-digit growth in biologic drug delivery and pharmacy automation, alongside competitive share gains in the Alaris pump business.
Thursday’s results will test whether that momentum can persist in a leaner, more focused organization as BD enters what analysts have called a pivotal transition year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates BDX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if BDX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?